Thus a better knowledge of the optimal HCMV IgG epitopes on the one hand, and an understanding of the action of viral FcγR antagonists on the other hand, could provide us with a basis for the targeted induction or even rational synthetic design of IgG molecules that allow an improved immunotherapy of HCMV diseases. This evidence concerns the gene FCGR2A and glycogen storage disease VI.